Rosuvastatin and the statin wars - The way to peace

Lancet

Volumn 364, Issue 9450, 2004, Pages 1997-1999

  Meyboom, Ronald H B ^a   Ralph Edwards, I ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH PRACTITIONER; HEPATITIS; HUMAN; HYPERLIPIDEMIA; MORBIDITY; MYOPATHY; NOTE; PANCREATITIS; POLYNEUROPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 9944221557     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17525-9     Document Type: Note

References (21)

1. Witts LJ. Adverse reactions to drugs. BMJ. 5470:1965;1081-1086
2. Editorial. The statin wars: why AstraZeneca must retreat. Lancet. 362:2004;1341
3. AstraZeneca Dear Doctor letter. http://www.astrazeneca.ca/E/news/ CRESTOR%20-%20European%20Prescribing%20Information%20Change.pdf (accessed Nov 4, 2004).
4. US Food and Drug Administration. FDA public health advisory for Crestor (rosuvastatin). June 9, 2004: http://www.fda.gov/cder/drug/advisory/crestor.htm (accessed Nov 9, 2004).
5. Begaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 288:2002;1588
6. Florentinus SR, Heerdink ER, Klungel O, de Boer A. Should rosuvastatin be withdrawn from the market. Lancet. 364:2004;1577-1578
7. Edwards IR. The accelerating need for pharmacovigilance. J R Coll Physicians Lond. 34:2000;48-51
8. Griffin MR, Stein CM, Wayne AR. Postmarketing surveillance for drug safety: surely we can do better. Clin Pharm Ther. 75:2004;491-494
9. Medicinal products for human use and veterinarian medicinal products: volume 9 - Pharmacovigilance. http://www.eudravigilance.org/human/docs/Vol9en. pdf (accessed Nov 4, 2004).
10. EudraVigilance. Pharmacovigilance in the European economic area. Sept 21, 2004: http://www.eudravigilance.org/human/index.asp (accessed Nov 4, 2004).
11. Medawar C, Herxheimer A, Bell A, Jofre S. Paroxetine, Panorama, and user reporting of ADRs: consumer intelligence matters in clinical practice and post-marketing drug surveillance. Int J Risk Safety Med. 15:2002;161-169
12. Meyboom RHB, Egberts ACG. Comparing therapeutic benefit and risk. Therapie. 54:1999;29-34
13. Uhl K, Honig P. Risk management of marketed drugs: FDA and the interface with the practice of medicine. Pharmacoepidemiol Drug Saf. 10:2001;205-208
14. Abraham J, Sheppard J. The therapeutic nightmare: the battle over the world's most controversial sleeping pill. 2000;Earthscan Publications, London
15. Medawar C, Hardon A. Medicines out of control? 2004;Aksant Academic Publishers, Amsterdam
16. Inman WHW. Don't tell the patient. 1999;Highland Park Productions, Bishop Waltham, Hampshire
17. Horton R. Lotronex and the FDA: a fatal erosion of integrity. Lancet. 357:2001;1544-1545
18. Van Egmond-Vettenbrug JS, Ter Steege H. Marketingplannen voor UR-geneesmiddelen: de feitelijke stand van zaken. July, 2001;Inspectie voor de Gezondheidszorg, Den Haag
19. Evaluatie Stichting CGR 2003. IGZ/H/RT 04-500-90. Den Haag: Inspectie voor de Gezondheidszorg, June 29, 2004.
20. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH E2E: pharmacovigilance planning. Draft version 4.1. Geneva: ICH Secretariat, Nov 11, 2003.
21. Cohen JS. Should rosuvastatin be withdrawn form the market? Lancet. 364:2004;1579